Friday, March 15, 2013

International Stem Cell Corporation Technology for Deriving Neuronal Cell Published by Nature Publishing Group

CARLSBAD, Calif. – (Marketwire) -- March 15, 2013 -- International Stem Cell Corporation (OTCQB: ISCO) ( a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells announced today the publication of its breakthrough method of deriving neuronal cells for the treatment of Parkinson’s disease in Scientific Reports, a primary research publication from the publishers of Nature.

Parkinson's disease (PD) is a common neurodegenerative disorder caused by a progressive loss of dopamine-producing neurons resulting in gradual dysfunction of the motor system.  Pharmacological treatments are useful in the relatively early stage of the disease, but the continuous use of pro-dopaminergic medication eventually becomes ineffective and can worsen some of the motor symptoms.  ISCO is developing a treatment for PD based on replacing the lost neurons with new neuronal cells derived from human parthenogenetic stem cell (hpSC).  To this end ISCO has developed a sophisticated and efficient manufacturing process for neuronal cells which has now been published in the peer-reviewed journal Scientific Reports.

The paper describes the technology, developed by ISCO's R&D team, for producing highly pure populations of GMP-grade neuronal cells suitable for pre-clinical studies and clinical trials.  The neuronal cells created using this approach are further characterized using a number of analytical methods and shown to function in a similar manner to adult cells.  Moreover, neuronal cells produced using this new method, express greater levels of dopamine, the neurotransmitter central to PD, than previously reported approaches.  Furthermore, these hpSC-derived neuronal cells are cryopreservable and can be stored frozen, and provides a practical route to creating neurons of sufficient quality to be used to treat Parkinson’s disease patients. 
“It is important that our research is reviewed and validated by the scientific community”, commented Dr. Andrey Semechkin, CEO and Co-Chairman, “and being able to publish in a Nature-branded, journal provides confirmation of the quality of ISCO’s scientific research”
The full-text of the publication can be found at

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products.  ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos.  ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (, and stem cell-based skin care products through its subsidiary Lifeline Skin Care ( More information is available at
To receive ongoing corporate communications via email, visit:

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: and

International Stem Cell Corporation
Dr. Simon Craw, Executive Vice President
Phone: 760-940-6383

Dr. Ruslan Semechkin, Vice President, R&D
Phone: 760-940-6383

Investor Relations:
MZ Group
Mark McPartland
Senior Vice President
Phone: 212-301-7130

No comments:

Post a Comment